U.S. market Open. Closes in 5 hours 14 minutes

AVXL | Anavex Life Sciences Corp. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 8.39 - 8.85
52 Week Range 3.25 - 14.44
Beta 1.14
Implied Volatility 98.87%
IV Rank 24.72%
Day's Volume 1,371,671
Average Volume 1,323,844
Shares Outstanding 85,064,200
Market Cap 729,850,836
Sector Healthcare
Industry Biotechnology
IPO Date 2006-08-02
Valuation
Profitability
Growth
Health
P/E Ratio -15.60
Forward P/E Ratio -9.76
EPS -0.55
1YR Price Target 39.50
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 40
Country USA
Website AVXL
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
*Chart delayed
Analyzing fundamentals for AVXL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see AVXL Fundamentals page.

Watching at AVXL technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on AVXL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙